StockIQ.techPfizer Inc. (PFE) Stock Analysis
Free AI-powered analysis and research for Pfizer Inc. stock
Sector: Healthcare
PFE snapshot
Data as of 9 Oct 2026 close. Updated daily.
Pfizer Inc. scores 51/100 on StockIQ's model, which reads as mixed signals overall. The price is above its 200-day average and at 83% of its 52-week range, up 14.1% over the past year. Latest reported figures show a profit margin of 6.8%, return on equity of 5.0% and revenue growth of +2.6%.
What is driving the score
- RSI Neutral: +5
- Strong Uptrend: +12
- MACD Bearish: -8
- High P/E (36.2): -10
- Weak Liquidity (1.27 Current Ratio): -5
- Above MA200: +4
- Positive YTD (+14.1%): +3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full PFE report
Pfizer Inc. (PFE) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze PFE Now →📰 Latest Update
Four Analysts Raised Their Pfizer Targets in One Week Without an Upgrade. Here’s Where the Stock Could Go By 2030
Sat, October 10, 2026 at 4:06 PM UTC 4 min read
In the past week, four analysts have raised their price targets for Pfizer (PFE) without issuing formal upgrades. This shift indicates growing confidence in the company's long-term prospects, potentially driven by its robust pipeline and ongoing developments in its pharmaceutical offerings. For investors, these upward revisions suggest a positive outlook for PFE's stock performance, with analysts projecting significant growth by 2030.